Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
22.65B
Market cap22.65B
Price-Earnings ratio
16.21
Price-Earnings ratio16.21
Dividend yield
Dividend yield
Average volume
2.22M
Average volume2.22M
High today
$115.46
High today$115.46
Low today
$112.84
Low today$112.84
Open price
$114.92
Open price$114.92
Volume
1.70M
Volume1.70M
52 Week high
$115.56
52 Week high$115.56
52 Week low
$66.83
52 Week low$66.83

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $114.21. The company's market cap stands at 22.65B, with a P/E ratio of 16.21.

During the trading session on 2026-07-01, Incyte(INCY) shares reached a daily high of $115.46 and a low of $112.84. At a current price of $114.21, the stock is +1.2% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 1.7M, compared to an average daily volume of 2.22M.

The stock's 52-week range extends from a low of $66.83 to a high of $115.56.

The stock's 52-week range extends from a low of $66.83 to a high of $115.56.

INCY News

Simply Wall St 22m
Incyte Stock May Be 33% Overvalued After Opzelura EU Win

Incyte stock has delivered a strong 82.6% return over the past three years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiple...

Incyte Stock May Be 33% Overvalued After Opzelura EU Win
Investing.com 2d
H.C. Wainwright reiterates Incyte stock rating on EU label expansion - Investing.com

...

H.C. Wainwright reiterates Incyte stock rating on EU label expansion - Investing.com
TipRanks 5d
Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know

Incyte (INCY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...

Analyst ratings

55%

of 29 ratings
Buy
41.4%
Hold
55.2%
Sell
3.4%

More INCY News

TipRanks 5d
Incyte announces positive CHMP opinion of Opzelura Cream

Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the...

TipRanks 5d
Incyte price target raised to $113 from $103 at UBS

UBS raised the firm’s price target on Incyte (INCY) to $113 from $103 and keeps a Neutral rating on the shares. The firm sees biopharma value stocks such as Inc...

Simply Wall St 5d
Incyte Lands Fresh Clinical Wins, Is It Fully Valued?

Incyte (INCY) stock is drawing fresh attention after a run of clinical and regulatory updates, including pivotal lymphoma data, positive rare disease results, e...

Incyte Lands Fresh Clinical Wins, Is It Fully Valued?

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.